肺癌患者化疗后骨髓抑制45例分析

Analysis of Myelosuppression after Chemotherapy in 45 Patients with Lung Cancer

目的：了解德阳市第二人民医院（以下简称＂我院＂）肺癌患者化疗后骨髓抑制的发生特点和影响因素,为临床安全用药提供参考。方法：对我院2013—2014年所有肺癌患者化疗后的骨髓抑制发生情况进行回顾性分析。结果：45例肺癌患者化疗后有32例（71.1%）发生骨髓抑制,有19例（42.2%）为重度骨髓抑制;骨髓抑制主要发生在化疗后的两周内;50~59岁年龄段患者的发生率最高;小细胞肺癌患者化疗后骨髓抑制的发生率（100.0%）高于非小细胞肺癌（63.9%）;多药联合化疗的骨髓抑制发生率（87.5%）比单药化疗（52.4%）高;含铂类药的化疗方案骨髓抑制发生率（78.8%）比不含铂类的化疗方案（50.0%）高,差异均有统计学意义（P〈0.05）。结论：肺癌患者化疗后骨髓抑制的发生率较高,临床医师与临床药师要重点关注患者年龄、化疗方案、肺癌类型及骨髓抑制的发生时间,降低骨髓抑制的发生风险,并通过积极治疗减轻对患者的损害,促进患者用药安全。

OBJECTIVE： To investigate the characteristics and influence factors of myelosuppression after chemotherapy in patients with lung cancer in the Second People＇s Hospital of Deyang（ hereinafter referred to as ＂our hospital＂）,and to provide reference for the medication safety. METHODS： The clinical data of myelosuppression after chemotherapy in patients with lung cancer admitted into our hospital during 2013-2014 were retrospectively analyzed. RESULTS： Of the 45 cases with lung cancer,32 cases（ 71. 1%） had myelosuppression after chemotherapy,and 19 cases（ 42. 2%） were severe.Myelosuppression mainly occurred in two weeks after chemotherapy,and the age stage of 50-59 year-old had the highest incidence rate. The incidence of myelosuppression after chemotherapy of patients with small cell lung cancer was higher than non small cell lung cancer（ 100. 0% VS 63. 9%）. The incidence of myelosuppression after combined chemotherapy was higher than single agent chemotherapy（ 87. 5% VS 52. 4%）. The incidence of myelosuppression induced by chemotherapycontaining platinum drugs was higher than that without containing platinum（ 78. 8% VS 50. 0%）,and the differences were statistical significance（ P 0. 05）. CONCLUSIONS： The incidence of myelosuppression after chemotherapy of patients with lung cancer was relatively high. Thus,the medical staff should focus on age,chemotherapy scheme,type of lung cancer and the occurrence time of myelosuppression,so as to reduce the risks of myelosuppression,relief damages on patients by active treatment,and promote medication safety in patients.